Oppenheimer Asset Management Inc. Invests $1.04 Million in Ingevity Corporation $NGVT

Oppenheimer Asset Management Inc. acquired a new stake in shares of Ingevity Corporation (NYSE:NGVT) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 13,890 shares of the company’s stock, valued at approximately $1,037,000.

Several other hedge funds also recently bought and sold shares of the business. AQR Capital Management LLC boosted its stake in shares of Ingevity by 10.9% during the first quarter. AQR Capital Management LLC now owns 13,410 shares of the company’s stock valued at $518,000 after purchasing an additional 1,323 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Ingevity by 5.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,790 shares of the company’s stock worth $863,000 after buying an additional 1,080 shares during the period. Empowered Funds LLC increased its stake in Ingevity by 12.9% in the 1st quarter. Empowered Funds LLC now owns 5,181 shares of the company’s stock worth $205,000 after buying an additional 594 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Ingevity by 311.8% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 600,380 shares of the company’s stock valued at $23,769,000 after buying an additional 454,579 shares in the last quarter. Finally, Jane Street Group LLC boosted its position in Ingevity by 306.1% in the 1st quarter. Jane Street Group LLC now owns 88,883 shares of the company’s stock valued at $3,519,000 after buying an additional 66,995 shares during the period. Institutional investors own 91.59% of the company’s stock.

Ingevity Trading Down 0.3%

Ingevity stock opened at $76.53 on Monday. The stock has a 50-day moving average of $73.57 and a two-hundred day moving average of $71.66. The company has a debt-to-equity ratio of 22.52, a quick ratio of 1.15 and a current ratio of 1.61. Ingevity Corporation has a one year low of $45.85 and a one year high of $79.29. The stock has a market cap of $2.63 billion, a PE ratio of 52.06 and a beta of 1.16.

Ingevity (NYSE:NGVT) last issued its quarterly earnings results on Wednesday, July 29th. The company reported $1.74 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.33 by $0.41. The business had revenue of $314.10 million for the quarter, compared to analyst estimates of $312.20 million. Ingevity had a net margin of 4.65% and a return on equity of 284.70%. Ingevity has set its FY 2026 guidance at 5.000-5.450 EPS. On average, research analysts anticipate that Ingevity Corporation will post 5.4 EPS for the current fiscal year.

Insider Activity

In other Ingevity news, CEO David H. Li sold 5,000 shares of Ingevity stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $76.62, for a total transaction of $383,100.00. Following the completion of the sale, the chief executive officer owned 135,636 shares of the company’s stock, valued at approximately $10,392,430.32. The trade was a 3.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ryan C. Fisher sold 2,709 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $73.72, for a total value of $199,707.48. Following the sale, the senior vice president owned 15,722 shares in the company, valued at approximately $1,159,025.84. The trade was a 14.70% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 8,205 shares of company stock valued at $616,779 over the last ninety days. 0.88% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

NGVT has been the subject of several research analyst reports. Wall Street Zen downgraded shares of Ingevity from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 1st. Weiss Ratings raised Ingevity from a “sell (d-)” rating to a “hold (c-)” rating in a research note on Friday, July 31st. Two equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $80.00.

About Ingevity

Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.

The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.